

Gibson Dunn Advises Arrowhead Pharmaceuticals on Asset Purchase Agreement Between Sanofi and Visirna Therapeutics

Firm News | August 11, 2025

Gibson Dunn is advising Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran in Greater China.

Led by partner Karen Spindler, our corporate team includes partner Jin Hee Kim and associates Paul Rafla and Sonari Chidi. Partners Pamela Lawrence Endreny and Benjamin Rapp and associate Ryan Rott are advising on tax; partner Cassandra Gaedt-Scheckter and associate Courtney Wang are advising on data privacy; and partner John Partridge and of counsel Ning Ning are advising on compliance.

Related People

[Karen A. Spindler](#)

[Jin Hee Kim](#)

[Paul Rafla](#)

[Sonari Chidi](#)

[Pamela Lawrence Endreny](#)

[Benjamin Rapp](#)

[Ryan Rott](#)

[Cassandra L. Gaedt-Scheckter](#)

[Courtney Wang](#)

[John D.W. Partridge](#)

[Ning Ning](#)

Related Capabilities

[Mergers and Acquisitions](#)